Autolus Therapeutics plc
Autolus Therapeutics plc, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on developing innovative T cell therapies for cancer treatment. Founded in 2014, Autolus has rapidly established itself in the cell and gene therapy industry, with significant operational presence in Europe and the United States. The company is renowned for its proprietary technology platform, which enables the creation of next-generation T cell therapies designed to enhance patient outcomes. Autolus's lead product candidates, including AUTO1 and AUTO3, showcase unique mechanisms that target various malignancies, setting them apart in a competitive market. With a commitment to advancing cancer care, Autolus Therapeutics has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of immuno-oncology.
DitchCarbon Score
How does Autolus Therapeutics plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Autolus Therapeutics plc's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Autolus Therapeutics plc's reported carbon emissions
In 2023, Autolus Therapeutics plc reported total carbon emissions of approximately 5,800 kg CO2e per employee, reflecting their operational impact on the environment. This figure represents a significant increase from 2022, where emissions were about 2,330 kg CO2e per employee. The emissions data does not specify Scope 1, 2, or 3 categories, indicating a lack of detailed disclosure in these areas. Despite the increase in emissions per employee, Autolus has not set specific reduction targets or initiatives, nor do they participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of formal commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. As a UK-based biopharmaceutical company, Autolus operates within an industry that is increasingly scrutinised for its environmental impact. The lack of cascaded emissions data from a parent organisation indicates that their reporting is independent, focusing solely on their operational footprint. Overall, while Autolus Therapeutics plc has reported emissions data, the absence of reduction targets and detailed scope categorisation highlights an opportunity for the company to enhance its climate commitments and transparency in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Autolus Therapeutics plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
